Session » Vasculitis Poster III

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 3034

A Comparative Metabolomic Evaluation of Behcet’s Disease with Arthritis and Seronegative Arthritis Using Synovial Fluid

9:00AM-11:00AM: Abstract Number: 3059

Abnormal Body Composition in Takayasu Arteritis Patients: Role of Inflammatory Cytokines and Adipokines

9:00AM-11:00AM: Abstract Number: 3045

Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?

9:00AM-11:00AM: Abstract Number: 3047

Association Between Red Blood Cell Distribution Width and Disease Activity in Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 3051

Bronchial Artery Enlargement May Cause Recurring Hemoptysis in Behçet’s Syndrome Patients with Pulmonary Artery Involvement Despite Response to Treatment

9:00AM-11:00AM: Abstract Number: 3052

Budd-Chiari Syndrome in Behçet’s Disease:a Retrospective Multicenter Study

9:00AM-11:00AM: Abstract Number: 3057

Can We Differentiate Takayasu’s Arteritis from Atherosclerosis Using Carotid Artery Doppler Usg?

9:00AM-11:00AM: Abstract Number: 3064

Cardiac Manifestation of Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 3072

Childhood Takayasu Arteritis. a Single Center Experience

9:00AM-11:00AM: Abstract Number: 3066

Clinical Features and Treatments of Takayasu Arteritis Complicated with Ulcerative Colitis

9:00AM-11:00AM: Abstract Number: 3049

Cognitive Dysfunction in Chronic Progressive Neuro-Behçet’s Disease: Comparative Study of the Brainstem and Hippocampus Region Using Brain Magnetic Resonance Imaging

9:00AM-11:00AM: Abstract Number: 3068

Damage Assessment in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 3065

Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Takayasu’s Arteritis in Large Healthcare Administrative Databases

9:00AM-11:00AM: Abstract Number: 3050

Evaluation of Olfactory Function in Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 3055

Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 3062

Frequency, Presentation and Outcome of Takayasu Arteritis in Western Australia

9:00AM-11:00AM: Abstract Number: 3035

HLA B51 and Possible Associated Autoimmune Disorders Other Than Behcets Disease: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 3043

IL-17 Expression By Lymphocytes Is Higher in Behcet’s Disease Compared to Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 3056

Increased Circulating Th17 Cells, Serum IL-17 and Serum IL-23 in Takayasu’s Arteritis

9:00AM-11:00AM: Abstract Number: 3041

Long Term Biological Therapy in Uveitis Refractory Due to Behçet’s Disease. Multicenter Study of 165 Patients.

9:00AM-11:00AM: Abstract Number: 3069

Long Term Follow-up Results of Endovascular Repair in the Management of Arterial Stenosis Caused By Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 3044

Microparticles (MPs) Derived from Cell Plasma Membranes Are Increased in Behcet’s Syndrome (BS) and a Low Ratio of Tissue Factor Pathway Inhibitor Positive Mps to Tissue Factor Positive Mps (TFPI/TF) Is Associated with Thrombosis

9:00AM-11:00AM: Abstract Number: 3067

Microscopic Colitis in Patients with Takayasu Arteritis; A Potential Association Between the Two Disease Entities

9:00AM-11:00AM: Abstract Number: 3058

NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 3063

Ocular Findings and Ocular Blood Flow Changes in Takayasu Arteritis: A Subclinical Reduction in Blood Flow with a Milder Clinical Course of Retinopathy

9:00AM-11:00AM: Abstract Number: 3070

Outcome of Pregnancies in Patients with Takayasu Arteritis with Special Focus on Risk Factors and Disease Activity

9:00AM-11:00AM: Abstract Number: 3053

Patients Treated for Behcet Syndrome in the US Have Higher Disease Activity Scores at Presentation If They Fulfill ISG Criteria and If They Are Females, However Have Less Severe Disease Overall

9:00AM-11:00AM: Abstract Number: 3073

Patterns of Vascular Involvement in Childhood Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 3033

Polyarteritis Nodosa and Cutaneous Arteritis: Are They Distinct Diseases?

9:00AM-11:00AM: Abstract Number: 3039

Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease

9:00AM-11:00AM: Abstract Number: 3040

Predictive Factors of Long-Term Clinical Outcome in Patients with Ocular Involvement Secondary to Behcet’s Syndrome

9:00AM-11:00AM: Abstract Number: 3032

Role of Adenosine and Neutrophils in Inflammation Associated with Mutations in CECR1 Gene

9:00AM-11:00AM: Abstract Number: 3037

Serum Anti-Lysozyme Is Associated with Disease Activity of Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 3038

Serum CXCL8, 10 and 12 Are Increased in Patients with Behcet’s Disease and CXCL10 Levels Are Correlated with Number of Erythema Nodosum

9:00AM-11:00AM: Abstract Number: 3071

Takayasu’s Arteritis and Pregnancy

9:00AM-11:00AM: Abstract Number: 3054

Takayasu’s Arteritis Associated with Behçet’s Syndrome: A Case Series of 8 Patients

9:00AM-11:00AM: Abstract Number: 3060

The Assessment of Disease Activity in Takayasu Arteritis; Six Years Experience from a Single Center

9:00AM-11:00AM: Abstract Number: 3036

The Association Between Behcet’s Disease, Myelodysplastic Syndrome and Trisomy 8

9:00AM-11:00AM: Abstract Number: 3061

Tocilizumab in Refractory Takayasu Arteritis. a Multicenter Study

9:00AM-11:00AM: Abstract Number: 3042

Tocilizumab in Refractory Uveitis Associated with Behçet’s Disease. Multicenter Study of 7 Patients.

9:00AM-11:00AM: Abstract Number: 3046

Venous Disease-Specific Quality-of-Life Is Impaired in Patients with Vascular Behcet’s Disease

9:00AM-11:00AM: Abstract Number: 3048

Work Disability over Time in Behcet’s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].